Critical Analysis: Prestige Consumer Healthcare (NYSE:PBH) & Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics (NASDAQ:UNCY) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Valuation & Earnings

This table compares Unicycive Therapeutics and Prestige Consumer Healthcare”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56 million	($1.75)	-2.77
Prestige Consumer Healthcare	$1.09 billion	1.96	$190.30 million	$3.57	12.58

Prestige Consumer Healthcare has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Unicycive Therapeutics and Prestige Consumer Healthcare, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	1	5	0	2.57
Prestige Consumer Healthcare	1	3	2	0	2.17

Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 287.40%. Prestige Consumer Healthcare has a consensus price target of $70.75, indicating a potential upside of 57.48%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Prestige Consumer Healthcare.

Summary

Prestige Consumer Healthcare beats Unicycive Therapeutics on 8 of the 13 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.